Trump Announces Major Price Cuts for Two Weight-Loss Drugs; Pharma Representative Faints, Press Conference Interrupted | WPN World People News

On November 6, U.S. President Donald Trump announced that his administration had reached an agreement with pharmaceutical giants Eli Lilly and Novo Nordisk to drastically cut the prices of GLP-1–based weight-loss medications. In exchange, the government will remove tariffs previously imposed on the two companies. Under the deal, GLP-1 weight-loss injections will drop from over $1,000 to $245 per month, while the oral version will be priced at $149 per month.

According to the agreement, Medicare and Medicaid will begin covering weight-loss drugs, and a new government website called **TrumpRX.gov** will launch in January next year, offering discounted prescription drug prices. Eli Lilly and Novo Nordisk have also pledged to manufacture the medications within the United States.

A brief incident occurred during the press conference held in the Oval Office— a pharmaceutical company representative standing behind President Trump suddenly fainted, causing a temporary interruption. Dr. Mehmet Oz, whom Trump appointed as the head of the Centers for Medicare & Medicaid Services (CMS), provided immediate assistance. The representative is reportedly in stable condition and has not suffered any serious harm.